Abstract
Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have